BeyondSpring, Inc. - Ordinary Shares (BYSI): Price and Financial Metrics
GET POWR RATINGS... FREE!
BYSI POWR Grades
- Growth is the dimension where BYSI ranks best; there it ranks ahead of 75.37% of US stocks.
- BYSI's strongest trending metric is Value; it's been moving up over the last 42 days.
- BYSI ranks lowest in Momentum; there it ranks in the 4th percentile.
BYSI Stock Summary
- BYSI's price/sales ratio is 55.9; that's higher than the P/S ratio of 96.62% of US stocks.
- Revenue growth over the past 12 months for BEYONDSPRING INC comes in at 650.56%, a number that bests 98.53% of the US stocks we're tracking.
- In terms of volatility of its share price, BYSI is more volatile than 91.51% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to BEYONDSPRING INC, a group of peers worth examining would be XBIO, SINT, MTP, KOPN, and NVCN.
- BYSI's SEC filings can be seen here. And to visit BEYONDSPRING INC's official web site, go to www.beyondspringpharma.com.
BYSI Valuation Summary
- BYSI's price/sales ratio is 58.5; this is 2685.71% higher than that of the median Healthcare stock.
- BYSI's price/sales ratio has moved NA NA over the prior 72 months.
Below are key valuation metrics over time for BYSI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BYSI | 2023-02-17 | 58.5 | 3.0 | -1.2 | -0.7 |
| BYSI | 2023-02-16 | 59.1 | 3.0 | -1.2 | -0.7 |
| BYSI | 2023-02-15 | 59.7 | 3.0 | -1.3 | -0.7 |
| BYSI | 2023-02-14 | 56.5 | 2.9 | -1.2 | -0.6 |
| BYSI | 2023-02-13 | 61.4 | 3.1 | -1.3 | -0.7 |
| BYSI | 2023-02-10 | 64.2 | 3.3 | -1.4 | -0.8 |
BYSI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BYSI has a Quality Grade of C, ranking ahead of 27.77% of graded US stocks.
- BYSI's asset turnover comes in at 0.01 -- ranking 391st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows BYSI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.010 | 1 | -20.655 |
| 2021-03-31 | 0.007 | 1 | 85.551 |
| 2020-12-31 | 0.003 | 1 | -1154.275 |
| 2020-09-30 | 0.000 | NA | -49.454 |
| 2020-06-30 | 0.000 | NA | -21.489 |
| 2020-03-31 | 0.000 | NA | -2964.190 |
BYSI Price Target
For more insight on analysts targets of BYSI, see our BYSI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $61.17 | Average Broker Recommendation | 1.21 (Strong Buy) |
BYSI Stock Price Chart Interactive Chart >
BYSI Price/Volume Stats
| Current price | $1.21 | 52-week high | $3.45 |
| Prev. close | $1.16 | 52-week low | $0.54 |
| Day low | $1.15 | Volume | 123,310 |
| Day high | $1.25 | Avg. volume | 347,259 |
| 50-day MA | $2.08 | Dividend yield | N/A |
| 200-day MA | $1.46 | Market Cap | 47.10M |
BeyondSpring, Inc. - Ordinary Shares (BYSI) Company Bio
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies. The co is advancing its lead asset, Plinabulin, into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia.
Latest BYSI News From Around the Web
Below are the latest news stories about BEYONDSPRING INC that investors may wish to consider to help them evaluate BYSI as an investment opportunity.
BeyondSpring First Half 2022 Earnings: US$0.47 loss per share (vs US$0.93 loss in 1H 2021)BeyondSpring ( NASDAQ:BYSI ) First Half 2022 Results Key Financial Results Net loss: US$18.5m (loss narrowed by 49... |
BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After ImmunotherapyNEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been enrolled in BeyondSpring’s Phase 2 investigator-initiated trial with lead asset, Plinabulin, in combination with Merck’s anti-PD-1 therapy Keytruda® (pembrolizumab) and Docetaxel for previously treated patients with metastatic non-small c |
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing RulesNEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that on December 29, 2022, the Company received a written notification (the “Notification Letter on Compliance”) from Nasdaq that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). In the Notification L |
Individual investors who hold 50% of BeyondSpring Inc. (NASDAQ:BYSI) gained 153%, insiders profited as wellEvery investor in BeyondSpring Inc. ( NASDAQ:BYSI ) should be aware of the most powerful shareholder groups. And the... |
Why Are BeyondSpring Shares Trading Higher?BeyondSpring Inc (NASDAQ: BYSI) presented data from the lead asset, plinabulin, for the prevention of docetaxel-induced neutropenia (DIN) in non-small cell lung cancer (NSCLC) patients. In summary, data from 101 and 103 studies, plinabulin demonstrated a superior benefit for Gr4N, Gr3/4N, all GrN, and duration of severe neutropenia (DSN) compared to the control. There was a reduction in mean DSN of >1 day for plinabulin vs. control. In the 105 study, NSCLC pts with at least one febrile neutropen |
BYSI Price Returns
| 1-mo | -40.39% |
| 3-mo | -36.98% |
| 6-mo | 0.83% |
| 1-year | -45.00% |
| 3-year | -91.46% |
| 5-year | -95.49% |
| YTD | -35.64% |
| 2022 | -58.50% |
| 2021 | -62.87% |
| 2020 | -21.29% |
| 2019 | -17.33% |
| 2018 | -35.52% |
Loading social stream, please wait...